Synopsis: Gujarat Kidney and Super Speciality Limited has approved the acquisition of a 51 percent stake in Dubai-based Blue Tree Clinics LLC for Rs. 19.84 crore. The acquisition marks the company’s entry into the UAE healthcare market, expanding its service portfolio into plastic surgery, cosmetic laser treatments, dental care, and chiropractic services while strengthening its international growth strategy.
Shares of Gujarat Kidney and Super Speciality Limited are likely to remain in focus after the company announced the acquisition of a 51 percent stake in Dubai-based Blue Tree Clinics LLC through a Share Purchase Agreement. The board also approved conducting a postal ballot to seek shareholders’ approval for variation in the objects of its IPO and appointed an additional independent director.
Gujarat Kidney and Super Speciality Limited has a total market capitalization of approximately Rs. 1063 crore. The company’s shares were trading at Rs. 134.47 apiece the stock exchange, up by 2.66 percent. The stock has gained 2.79 percent over the last five trading sessions, while it has delivered gained 8.21 percent over the last month. The stock touched a 52-week high of Rs. 148 and a 52-week low of Rs. 98.
According to the company’s exchange filing, Gujarat Kidney and Super Speciality Limited will acquire a 51 percent equity stake in Blue Tree Clinics LLC, a UAE-based polyclinic, for a total consideration of Rs. 19.84 crore, payable in two tranches over a maximum period of 50 days. The acquisition will be completed through a cash transaction and does not involve any related-party transactions or promoter interest.
Blue Tree Clinics LLC, incorporated in 2012, operates in Dubai and offers a range of specialized healthcare services including plastic surgery, laser cosmetic treatments, general dentistry, and chiropractic care. During FY25, the clinic reported gross revenue of AED 10.54 million and net profit of AED 3.14 million, demonstrating a profitable operating business that Gujarat Kidney will now gain majority control over.
The acquisition represents a strategic milestone for Gujarat Kidney as it expands beyond India into one of the Middle East’s fastest-growing healthcare markets. Besides providing geographical diversification, the transaction broadens the company’s service offerings beyond its traditional multi-speciality hospital business, enabling it to participate in high-margin segments such as cosmetic healthcare, aesthetic medicine, specialized dental treatments, and wellness services.
The UAE healthcare sector continues to benefit from rising medical tourism, increasing healthcare expenditure, premium healthcare demand, and government initiatives to strengthen medical infrastructure. Dubai, in particular, has emerged as a global destination for cosmetic procedures and specialized healthcare services, creating long-term growth opportunities for healthcare providers with established local operations.
For investors, the acquisition could diversify the company’s revenue streams while providing access to an international market with higher-value healthcare services. The profitable operations of Blue Tree Clinics, coupled with opportunities for cross-border referrals, knowledge sharing, and expansion of specialized treatments, could support the company’s long-term earnings growth and strengthen its presence in the global healthcare industry.
Apart from the acquisition, the board also approved initiating a postal ballot process to seek shareholders’ approval for variation in the objects of its IPO and appointed Dr. Paresh Dhoti as an Additional Non-Executive Independent Director for a five-year term, subject to shareholders’ approval. These developments reflect the company’s focus on strengthening governance while supporting its future expansion plans.
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited is a multi-speciality healthcare provider offering advanced tertiary and quaternary medical services across nephrology, urology, cardiology, oncology, orthopaedics, gastroenterology, neurology, critical care, and other specialized disciplines. The company operates NABH-accredited hospitals equipped with modern diagnostic and surgical infrastructure, while also expanding its presence through strategic domestic and international healthcare initiatives.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
